Source comparison
Thymosin Alpha-1 Side Effects: Safety Comparison
Understanding thymosin alpha-1's safety profile requires context. How it compares to other immunomodulatory therapies used for similar indications. The table below contrasts adverse event incidence across peptide and biologic immune therapies. Thymosin Alpha-1
This comparison does not assign a generated winner or score.
- Understanding thymosin alpha-1's safety profile requires context. How it compares to other immunomodulatory therapies used for similar indications. The table below contrasts adverse event incidence across peptide and biologic immune therapies.
- Thymosin Alpha-1
- TLR modulation, dendritic cell maturation
- Injection site reactions (3.8%), transient myalgia (<1%)
- None documented in controlled trials
- <0.5%
- Exceptionally well-tolerated; adverse event profile among the lowest of any immunomodulator
- Interferon Alpha-2b
- Type I interferon receptor agonist
- Flu-like symptoms (60–80%), fatigue (70%), depression (30–40%), neutropenia (20%)
- Hepatotoxicity, severe depression, autoimmune thyroiditis
- 10–15%
- High systemic toxicity limits tolerability; requires frequent monitoring
- Interleukin-2 (IL-2)
- IL-2 receptor agonist, T-cell proliferation
- Capillary leak syndrome (60%), hypotension (50%), fever/chills (80%)
- Pulmonary edema, myocardial infarction, renal dysfunction
- 15–25%
- Reserved for refractory cases; adverse event burden requires inpatient administration
- Imiquimod (topical TLR7 agonist)
- TLR7 activation, local cytokine induction
- Application site erythema/erosion (80–90%), pruritus (40%), fatigue (10%)
- Rare systemic hypersensitivity
- 5–8%
- Local reactions expected and dose-limiting; systemic absorption minimal
- BPC-157
- Angiogenesis, tissue repair signaling
- Injection site reactions (<5%), no systemic AEs reported in human studies
- None documented
- <1%
- Similar safety profile to thymosin alpha-1; endogenous peptide with minimal immunogenicity